Axsome Therapeutics (AXSM) Earnings Date & Reports
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
AXSM is expected to report earnings to fall 33.25% to -84 cents per share on August 10
Axsome Therapeutics (AXSM) First Quarter 2026 Earnings Recap: Revenue Surges 57% on Product Momentum
Key Takeaways
- Total net product revenue reached $191.2 million, a 57% increase year-over-year.
- Net loss widened to $64.5 million, or $1.26 per diluted share, compared to consensus expectations of -$0.83 EPS.
- Auvelity drove major growth with net product revenue of approximately $153.2 million, supported by Sunosi and Symbravo.
- Shares surged over 10% in pre-market trading post-earnings, reflecting optimism around commercial execution and pipeline.
- Management reaffirmed revenue growth trajectory and raised peak sales guidance for Auvelity to $8 billion.
Earnings Context and Why It Matters
Axsome Therapeutics, a biopharmaceutical company specializing in central nervous system (CNS) disorders, reported its First Quarter 2026 results amid accelerating commercial momentum. With three marketed products—Auvelity for major depressive disorder (MDD), Sunosi for excessive daytime sleepiness, and the newly approved Symbravo—this quarter highlights the company's transition toward sustained revenue growth. Investors are focused on sales ramp-up, margin expansion, and pipeline catalysts, as Axsome navigates launch investments in a competitive CNS market. Strong top-line performance underscores payer coverage gains and prescriber adoption, critical for long-term profitability in biotech.
Axsome reported total net product revenue of $191.2 million for the First Quarter 2026, surpassing some estimates around $190.5 million and marking a robust 57% rise from $121.5 million in Q1 2025. Auvelity contributed significantly, with net sales nearing $153 million, fueled by expanded indications and market penetration. Sunosi and initial Symbravo contributions rounded out the portfolio.
Despite revenue strength, the company posted a net loss of $64.5 million, or $1.26 per diluted share, wider than the prior year's $59.4 million loss ($1.22 per share) and missing Wall Street's -$0.83 EPS consensus. Elevated selling, general, and administrative (SG&A) expenses from Symbravo launch and research and development (R&D) investments for pipeline assets drove the shortfall.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
AXSM shares jumped approximately 11% in pre-market trading on May 5, 2026, reaching around $212, bucking the EPS miss. Investors prioritized the revenue beat, YoY growth, and positive business updates—including FDA approval expansions for Auvelity—over near-term losses. Analysts noted strong commercial traction, with some raising price targets, signaling confidence in execution despite launch costs.
Forward Outlook and Key Factors to Monitor
Management expects revenue growth to persist through 2026, driven by Auvelity's frontline positioning in MDD and new Alzheimer's disease agitation (ADA) label, alongside Symbravo's commercial rollout. Peak sales guidance for Auvelity was uplifted to at least $8 billion, evenly split between MDD and ADA, reflecting optimistic market potential.
Key catalysts include Symbravo launch progress, payer reimbursements, and gross-to-net (GTN) margin improvements as volume scales. Investors should track R&D updates on late-stage assets like AXS-07 for migraine and solriamfetol expansions.
Cost discipline remains vital amid elevated SG&A from sales force expansion. Broader CNS market dynamics, such as generic pressures and reimbursement trends under the Inflation Reduction Act (IRA), will influence margins. Cash position supports operations, but profitability timelines hinge on expense leverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology